204 related articles for article (PubMed ID: 23374809)
1. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
3. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
[TBL] [Abstract][Full Text] [Related]
4. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.
Hara N; Nishiyama T; Takizawa I; Saito T; Kitamura Y; Takahashi K
Urology; 2010 Jun; 75(6):1441-5. PubMed ID: 20110105
[TBL] [Abstract][Full Text] [Related]
5. Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy.
Komatsu S; Hara N; Ishizaki F; Nishiyama T; Takizawa I; Isahaya E; Kawasaki T; Takahashi K
Prostate; 2012 Aug; 72(11):1207-13. PubMed ID: 22213519
[TBL] [Abstract][Full Text] [Related]
6. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
7. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Isahaya E; Hara N; Nishiyama T; Hoshii T; Takizawa I; Takahashi K
Prostate; 2010 Feb; 70(2):155-61. PubMed ID: 19760629
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy: influence on serum and urinary androgen levels.
Olsson M; Ekström L; Schulze J; Kjellman A; Akre O; Rane A; Gustafsson O
Prostate; 2010 Feb; 70(2):200-5. PubMed ID: 19760638
[TBL] [Abstract][Full Text] [Related]
9. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
10. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
12. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
13. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone suppressibility and adrenal and ovarian venous effluents of 5α-reduced C19 conjugates in hyperandrogenic women.
Stanczyk FZ; Saxena T; Lobo RA
J Steroid Biochem Mol Biol; 2014 Jan; 139():73-7. PubMed ID: 24121067
[TBL] [Abstract][Full Text] [Related]
15. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
16. Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men.
Jiang J; Tang NL; Ohlsson C; Eriksson AL; Vandenput L; Liao C; Wang X; Chan FW; Kwok A; Orwoll E; Kwok TC; Woo J; Leung PC
Clin Chem; 2010 Nov; 56(11):1742-9. PubMed ID: 20855474
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
18. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
19. Androstane-3alpha,17beta-diol glucuronide as a steroid correlate of visceral obesity in men.
Tchernof A; Labrie F; Bélanger A; Prud'homme D; Bouchard C; Tremblay A; Nadeau A; Després JP
J Clin Endocrinol Metab; 1997 May; 82(5):1528-34. PubMed ID: 9141545
[TBL] [Abstract][Full Text] [Related]
20. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Smith MR
Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
